Otrexup (Methotrexate/PF) Patent Expiration, LOE Window & CMS Spending

Otrexup (Methotrexate/PF) by Antares/Otter: Off-Patent Genericized (AB Competition), 0 AB generics, $10.8M 2024 CMS Part D & Medicaid spend, and 14 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorAntares/Otter
FDA Application & PathwayReconciled (UNLINKED)
Exclusivity / Cliff HorizonOff-Patent Genericized (AB Competition)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity DateNot listed / N/A
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$10.8M
2024 Medicare Part D Spend$7.5M
2024 Medicaid Spend$3.2M
Reported Wholesale Price Change (CA SB 17)14 WAC filings (max 18.8% 2-yr change)